Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Sarcoma
•
Medical Oncology
•
Cancer of Unknown Primary
How would you treat someone with unknown primary metastatic SMARCA4 deficient tumor (high-grade tumor with rhabdoid morphology)?
Answer from: Medical Oncologist at Community Practice
Ponatinib might be useful. You might also see if a clinical trial is available.http://clincancerres.aacrjournals.org/content/24/8/1932
Sign In
or
Register
to read more
Answer from: Medical Oncologist at Academic Institution
Consider tazemetostat (epigenetic modifier via EZH2 nhibition) via compassionate use program.
Sign In
or
Register
to read more
5664
5676
Related Questions
How would you treat an unresectable epithelioid angiosarcoma invading the cavernous sinus, wrapping around the carotid artery?
Which patient characteristics or clinical factors guide the decision to use Doxorubicin and Trabectedin as first-line treatment for metastatic or unresectable leiomyosarcoma?
How would you manage an epidural spinal metastasis causing cord compression from rhabdomyosarcoma?
Is there a role for adjuvant chemotherapy in a young healthy patient with a large malignant phyllodes tumor of the breast with positive margins?
How would you approach adjuvant treatment in a patient with completely resected undifferentiated pleomorphic sarcoma of the chest wall that recurred after 2 years, initially treated with neoadjuvant radiation and resection?
What is the recommended approach for a 7 cm x 5 cm paraspinal subcutaneous desmoid tumor (T6 to T9) incidentally detected on PET CT during NSCLC monitoring, with confirmed growth over 18 months?
How do you approach an otherwise healthy patient with an incidental 1 mm GIST involving the serosal surface in terms of staging workup, EGD, and surveillance?
What is the preferred systemic therapy regimen for a patient in their 40s with untreated metastatic sarcomatoid carcinoma of unknown primary, presenting with hepatic lesions, abdominal lymphadenopathy, and a lytic bone lesion?
How do you approach adjuvant therapy for resected Stage I Ewing sarcoma of the kidney, and what chemotherapy regimen and cycle duration do you recommend?
How do you approach adjuvant chemotherapy in an adult with localized osteosarcoma who demonstrates 50–90% tumor necrosis on surgical pathology following neoadjuvant doxorubicin and cisplatin?